BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302535% above fair value
$403.60−9.66 (-2.34%)
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
BeOne Medicines shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
BeOne Medicines's shares outstanding was 1.51B at Jun 30, 2026. For fiscal 2025 it was 1.47B, up 7.8% from the year before. Over ten years it grew 29.6% a year on average. The highest annual figure on record is 1.47B in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.47B | +7.8% |
| FY2024 | Dec 31, 2024 | 1.37B | +0.9% |
| FY2023 | Dec 31, 2023 | 1.36B | +1.2% |
| FY2022 | Dec 31, 2022 | 1.34B | +11.2% |
| FY2021 | Dec 31, 2021 | 1.21B | +11.2% |
| FY2020 | Dec 31, 2020 | 1.09B | +39.0% |
| FY2019 | Dec 31, 2019 | 781M | +8.3% |
| FY2018 | Dec 31, 2018 | 721M | +32.7% |
| FY2017 | Dec 31, 2017 | 543M | +34.6% |
| FY2016 | Dec 31, 2016 | 404M | +264.9% |
| FY2015 | Dec 31, 2015 | 111M | +10.8% |
| FY2014 | Dec 31, 2014 | 100M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 1.51B | +2.9% |
| Q1 FY2026 | Mar 31, 2026 | 1.51B | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | 1.50B | +8.0% |
| Q3 FY2025 | Sep 30, 2025 | 1.49B | +8.1% |
| Q2 FY2025 | Jun 30, 2025 | 1.46B | +7.5% |
| Q1 FY2025 | Mar 31, 2025 | 1.45B | +6.6% |
| Q4 FY2024 | Dec 31, 2024 | 1.39B | +2.8% |
| Q3 FY2024 | Sep 30, 2024 | 1.38B | -1.0% |
| Q2 FY2024 | Jun 30, 2024 | 1.36B | +0.1% |
| Q1 FY2024 | Mar 31, 2024 | 1.36B | +0.1% |
| Q4 FY2023 | Dec 31, 2023 | 1.35B | +0.3% |
| Q3 FY2023 | Sep 30, 2023 | 1.39B | +3.3% |
| Q2 FY2023 | Jun 30, 2023 | 1.36B | +1.8% |
| Q1 FY2023 | Mar 31, 2023 | 1.35B | +1.7% |
| Q4 FY2022 | Dec 31, 2022 | 1.35B | +9.2% |
| Q3 FY2022 | Sep 30, 2022 | 1.35B | +11.6% |
| Q2 FY2022 | Jun 30, 2022 | 1.34B | +11.9% |
| Q1 FY2022 | Mar 31, 2022 | 1.33B | +5.9% |
| Q4 FY2021 | Dec 31, 2021 | 1.24B | +4.6% |
| Q3 FY2021 | Sep 30, 2021 | 1.21B | +5.0% |
| Q2 FY2021 | Jun 30, 2021 | 1.19B | +18.2% |
| Q1 FY2021 | Mar 31, 2021 | 1.26B | +25.1% |
| Q4 FY2020 | Dec 31, 2020 | 1.18B | +49.8% |
| Q3 FY2020 | Sep 30, 2020 | 1.15B | +47.0% |
| Q2 FY2020 | Jun 30, 2020 | 1.01B | +29.9% |
| Q1 FY2020 | Mar 31, 2020 | 1.01B | +29.8% |
| Q4 FY2019 | Dec 31, 2019 | 789M | +2.1% |
| Q3 FY2019 | Sep 30, 2019 | 781M | +5.6% |
| Q2 FY2019 | Jun 30, 2019 | 778M | +11.3% |
| Q1 FY2019 | Mar 31, 2019 | 775M | +15.5% |
| Q4 FY2018 | Dec 31, 2018 | 773M | +58.0% |
| Q3 FY2018 | Sep 30, 2018 | 740M | +23.2% |
| Q2 FY2018 | Jun 30, 2018 | 699M | +34.9% |
| Q1 FY2018 | Mar 31, 2018 | 671M | +29.8% |
| Q4 FY2017 | Dec 31, 2017 | 489M | +5.4% |
| Q3 FY2017 | Sep 30, 2017 | 601M | +40.3% |
| Q2 FY2017 | Jun 30, 2017 | 518M | – |
| Q1 FY2017 | Mar 31, 2017 | 516M | – |
| Q4 FY2016 | Dec 31, 2016 | 464M | – |
| Q3 FY2016 | Sep 30, 2016 | 428M | – |
See a number that looks wrong?